Abstract
Migraine is a complex, disabling neurological disorder, characterised by repeated bouts of headache and associated symptoms. The ongoing management of frequent migraine relies on preventive treatments and several drugs that have been approved for migraine prevention. However, the majority of these drugs have been developed for other indications, and their regular use is limited by side effects, patient comorbidities and/or inadequate efficacy. This lack of appropriate, well-tolerated treatments leaves a substantial number of sufferers with unmet treatment needs. New migraine-specific treatments are therefore sought. On the horizon is a new class of compounds, monoclonal antibodies, targeting the CGRP (calcitonin gene-related peptide) pathway. In this paper we present an overview of migraine, current preventive treatments and the new CGRP monoclonal antibodies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.